A PILOT TRIAL OF TANDEM AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOLLOWING HIGH-DOSE THIOTEPA AND CARBOPLATIN IN CHILDREN WITH POOR-RISK CENTRAL NERVOUS SYSTEM TUMORS

2004 ◽  
Vol 21 (7) ◽  
pp. 635-645 ◽  
Author(s):  
M. Fevzi Ozkaynak ◽  
Claudio Sandoval ◽  
Oya Levendoglu-Tugal ◽  
Somasundaram Jayabose
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Pilot Trial ◽  
Peripheral Blood Progenitor Cell ◽  
Central Nervous System Tumors ◽  
High Dose ◽  
Nervous System Tumors

Role of Parenteral Nutrition in Cancer Patients Undergoing High-Dose Chemotherapy Followed by Autologous Peripheral Blood Progenitor Cell Transplantation

2005 ◽  
Vol 91 (3) ◽  
pp. 237-240 ◽  
Author(s):  
Alfredo Tartarone ◽  
Jenna Wunder ◽  
Gianpiero Romano ◽  
Raffaele Ardito ◽  
Giovanni lodice ◽  
...  
Keyword(s):  
Parenteral Nutrition ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
Peripheral Blood Progenitor Cell ◽  
High Dose ◽  
Conditioning Regimens

High-dose chemotherapy followed by autologous bone marrow or peripheral blood progenitor cell transplantation represents a recognized option in the treatment of solid tumors and hematologic diseases. Patients receiving high-dose chemotherapy are traditionally supported with parenteral nutrition with the aim to prevent malnutrition secondary to gastrointestinal toxicity and metabolic alterations induced by the conditioning regimens. Nevertheless, well-defined guidelines for its use in this clinical setting are lacking and there are several areas of controversy.

Sign in / Sign up

Export Citation Format

Share Document